Current and future animal vaccine research activities at ILRI
Vish Nene8 International Congress on Ticks and Tick-Borne Pathogens (TTP8)
and 12 Biennial Conference, South Africa, 24-29 August 2014
Priority diseases targeted by the ILRI Vaccine Biosciences group
African swine fever (ASF) – swine African disease threatens the global $150 billion/year pig industry
Contagious bovine pleuropneumonia (CBPP) – cattle Regional losses to CBPP amount to ~ $60 million/year
East Coast fever (ECF) – cattle Regional losses exceed $300 million/year; kills ~ 1million cattle/year
Peste des petits ruminants (PPR) – small ruminants Losses in Kenya alone amount to ~ $13 million/year
Rift Valley Fever (RVF) – small ruminants, cattle and human 2006/7 outbreak in Kenya cost ~ $30 million
o 309 human cases in Kenya, Somalia and Tanzania; 140 deaths
Diagnostics are key components of a vaccine program New and more user-friendly tests – evidence based control programs
Vaccines save lives and livestock and contribute to food security and poverty alleviation
ILRI’s vaccine R & D pathway to impact
ILRI’s comparative advantage is mainly in the discovery phase to proof-of-principle under laboratory and field conditions.
Different entry points in pathway depending on disease targeted for control. Improvement of existing vaccines Development of subunit vaccines Laboratory and field based diagnostics
Establish key principles in livestock vaccinology and capacity
ILVAC - vaccine technologies (ilvac.net)
Top Related